136 related articles for article (PubMed ID: 6332672)
1. Effect of levamisole on cytotoxic T-cell-mediated immune resistance to L1210 murine leukemia in hyperimmune mice.
Gomi K; Morimoto M; Kataoka T
Cancer Immunol Immunother; 1984; 17(3):195-9. PubMed ID: 6332672
[TBL] [Abstract][Full Text] [Related]
2. [Effects of levamisole on methylcholanthrene-induced tumor. II. Potentiation of cytotoxic T-cell activities].
Gomi K; Morimoto M; Nomoto K
Gan To Kagaku Ryoho; 1982 Jul; 9(7):1269-76. PubMed ID: 6985196
[TBL] [Abstract][Full Text] [Related]
3. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T
Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
[TBL] [Abstract][Full Text] [Related]
5. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a murine leukemia L1210-specific T-cell clone displaying novel in vivo anti-tumor activity.
Nagase F; Ueda K; Nakashima I; Kawashima K; Isobe K; Nagura E; Yamada K; Yokochi T; Hasegawa Y; Yoshida T
Int J Cancer; 1986 Dec; 38(6):907-14. PubMed ID: 3491792
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes.
Slater LM; Sweet P; Stupecky M; Reynolds JT
Clin Immunol Immunopathol; 1995 Jun; 75(3):239-45. PubMed ID: 7768041
[TBL] [Abstract][Full Text] [Related]
8. Non-cytotoxic activity of pyran copolymer-induced macrophages associated with potentiation of tumour vaccine in recipient mice.
Kataoka T; Oh-hashi F
Cancer Immunol Immunother; 1985; 20(1):69-74. PubMed ID: 2998590
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.
Kawashima K; Isobe K; Nagase F; Yokochi T; Nagura E; Hasegawa Y; Morishita H; Yamada K; Nakashima I
Leuk Res; 1985; 9(7):935-9. PubMed ID: 4021540
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: studies on cell-mediated immunity and humoral antibody response.
Mantovani A; Spreafico F
Eur J Cancer (1965); 1975 Aug; 11(8):537-44. PubMed ID: 1222761
[No Abstract] [Full Text] [Related]
11. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
Bowlin TL; Prakash NJ; Edwards ML; Sjoerdsma A
Cancer Res; 1991 Jan; 51(1):62-6. PubMed ID: 1988107
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and amplifier cell production by tumor vaccines enhanced by concanavalin A.
Kataoka T; Oh-Hashi F; Sakurai Y
Gan; 1982 Apr; 73(2):193-205. PubMed ID: 6811360
[TBL] [Abstract][Full Text] [Related]
13. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
Ujiie T
Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
[TBL] [Abstract][Full Text] [Related]
14. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
Kataoka T; Oh-hashi F
Cancer Res; 1985 Jul; 45(7):2962-6. PubMed ID: 3873988
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of L1210 murine leukemia vaccine in vivo by levamisole.
Kataoka T; Tsukagoshi S; Sakurai Y; Okabe M
Gan; 1979 Aug; 70(4):515-9. PubMed ID: 510850
[TBL] [Abstract][Full Text] [Related]
16. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
Miura T; Maekawa T; Kurashige S; Mitsuhashi S
Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
[TBL] [Abstract][Full Text] [Related]
17. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
Baxevanis CN; Gritzapis AD; Spanakos G; Tsitsilonis OE; Papamichail M
Cancer Immunol Immunother; 1995 Jun; 40(6):410-8. PubMed ID: 7543022
[TBL] [Abstract][Full Text] [Related]
18. Induction of antitumor resistance to mouse leukemia L1210 by spergualins.
Ishizuka M; Masuda T; Mizutani S; Osono M; Kumagai H; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1986 Dec; 39(12):1736-43. PubMed ID: 3546237
[TBL] [Abstract][Full Text] [Related]
19. Immune rejection mechanisms in murine leukemia. I. Timing of tumor cell rejection process relative to the development of humoral and cell-mediated cytotoxic immune responses.
Ciavarra RP; Terres G
Int J Cancer; 1984 Nov; 34(5):681-8. PubMed ID: 6500745
[TBL] [Abstract][Full Text] [Related]
20. Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice.
Berd DA; Mitchell MS
Cancer Res; 1976 Nov; 36(11 Pt 1):4119-24. PubMed ID: 975053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
